Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
Drug trial aims to put the brakes on scarred lungs
Disease control TerminatedThis study tested whether an investigational drug called vixarelimab could slow the decline in lung function for people with two types of progressive lung scarring diseases. About 286 adults with either idiopathic pulmonary fibrosis or lung disease related to systemic sclerosis (…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
First human test of experimental cancer drug halted early
Disease control TerminatedThis early-stage study tested the safety of a new cancer drug called RO7759065, both alone and combined with an existing immunotherapy drug (atezolizumab), in patients with advanced solid tumors that could not be cured by other treatments. The main goal was to find a safe dose an…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Experimental drug tested for Hard-to-Treat bowel disease
Disease control TerminatedThis study tested an experimental drug called vixarelimab in people with moderate to severe ulcerative colitis who hadn't responded well to other treatments. The trial aimed to see if the drug could reduce bowel inflammation and symptoms over 12 weeks, and then explore longer-ter…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC